Cart
sales@molnova.com
p38 MAP Kinase Inhibitor Ⅵ
CAS No. 421578-46-3
p38 MAP Kinase Inhibitor Ⅵ( —— )
Catalog No. M36102 CAS No. 421578-46-3
p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 117 | In Stock |
|
| 5MG | 180 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 450 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 872 | In Stock |
|
| 500MG | 1737 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep38 MAP Kinase Inhibitor Ⅵ
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
-
Descriptionp38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24%.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number421578-46-3
-
Formula Weight332.42
-
Molecular FormulaC16H13FN2OS2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C(C)C2=C(S1)N=CN=C2SCC(=O)C1=CC=C(F)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Iroxanadine
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.
-
Eudesmin
Eudesmin shows antiinflammatory neuritogenic anticonvulsant and sedative effects the mechanism of eudesmin may be related to up-regulation of GABAA and GAD65 expressions and anti-apoptosis of neuron the in brain.50 microM (+)-eudesmin can induce neurite outgrowth and enhance nerve growth factor (NGF)-mediated neurite outgrowth from PC12 cells by stimulating up-stream MAPK PKC and PKA pathways.
-
Antimicrobial agent-...
Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment of cataracts, ulcerative colitis, meningitis and Kawasaki's disease and Parkinson's disease.
